InflammaSkin®

HUMAN PSORIASIS MODEL TO TEST ANTI-INFLAMMATORY DRUGS

T CELL-DRIVEN KEY PSORIASIS FEATURES

InflammaSkin is currently the only ex vivo human psoriasis model T cell-driven with a Th17/Th1 phenotype.

PROPHYLACTIC & THERAPEUTIC

This psoriasis model can be used to assess prophylactic treatments for up to 7 days and therapeutic treatments for up to 4 days.

TOPICAL, SYSTEMIC & SUBCUTANEOUS

We evaluate anti-inflammatory response to anti-psoriasis drugs after topical treatments, systemic treatment, or subcutaneous injection.

AVAILABLE AS A SERVICE

InflammaSkin model is available with or without adipose tissue as an in-house service.

Inflammaskin: psoriasis model. 100% human. ex vivo model. standardized. Th17/Th1 psoriasis-like. culture up to 7 days.

The only ex vivo skin inflammation model with a psoriasis-like phenotype

Genoskin developed a fully human T cell-driven ex vivo skin inflammation model based on the NativeSkin® explant technology. Resident T cells are activated in situ by injection into the skin. The injected skin models are then cultured for up to 7 days with a chemically-defined culture medium supplemented with a pro-inflammatory cytokine cocktail to induce Th17/Th1 T cell polarization.

InflammaSkin

A fully human model reproducing key psoriasis skin inflammation features

Histological analysis of InflammaSkin® model shows characteristic anomalies in the epidermis in contrast to non-inflamed NativeSkin® skin models. Epidermal activation is shown by the over-expression of the psoriasis-associated pro-inflammatory markers Keratin 16 (K16) and psoriasin (S100A7).

Histological characterization and expression of pro-inflammatory markers in InflammaSkin®, our psoriasis model.
Histological characterization and expression of pro-inflammatory markers in InflammaSkin®

The analysis of cytokine levels in culture media at day 7 shows sustained secretion of IL-17A and IL-22  (IFN-γ and TNF-α as well as the lack of IL-4 expression, data not shown) compared to non-inflamed NativeSkin® skin models, supporting successful activation and differentiation of Th17/Th1 cells.

cytokine release inflammation in psoriasis model
Release of pro-inflammatory cytokines from InflammaSkin® after 7 days of culture

A unique psoriasis model for anti-Th1/Th17 inflammatory drug testing

Daily topical application of betamethasone gel shows a restoration or preservation of epidermal integrity and viability after 7 days of prophylactic treatment when compared to untreated and normal skin (NativeSkin®), indicating anti-inflammatory effects. We obtained further improvement with the daily topically applied PDE-4 cream.

Histological characterization and epidermal markers expression after prophylactic treatment with betamethasone gel and PDE-4 inhibitor cream in psoriasis model InflammaSkin
Histological characterization and epidermal markers expression after prophylactic treatment with betamethasone dipropionate gel and PDE-4 inhibitor cream

We observed a significant decrease of pro-inflammatory cytokines IL-17A and IL-22 release from InflammaSkin® following a 7-day prophylactic treatment with bethamethasone gel compared to the vehicle gel. The same conclusion can be made with a 7-day prophylactic treatment with PDE-4 cream compared to the vehicle cream.

cytokine release inflammation after topical treatments in our psoriasis model, InflammaSkin
Release of pro-inflammatory cytokines from InflammaSkin® after 7 days of culture following prophylactic treatment

A fully human psoriasis model for prophylactic and therapeutic settings

InflammaSkin® model can be used to assess the efficacy of anti-inflammatory drugs targeting T cells as well as IL-17, IL-22 and TNF-α. Evaluation of efficacy can be performed following topical, systemic (dilution in the culture medium) or subcutaneous administration. We can evaluate both prophylactic (administration at day 0) and therapeutic treatment (administration at day 3).

Hypo-InflammaSkin

a proof-of-concept case study

The InflammaSkin technology was combined with the HypoSkin model to evaluate the efficacy of subcutaneous psoriasis biologics adalimumab.

Read more
Close up of psoriasis biologics adalimumab for subcutaneous injections in psoriasis model Hypo-InflammaSkin

InflammaSkin is available as an in-house service.

InflammaSkin is available in two formats, without and with adipose tissue, for topical and subcutaneous administration.

REFERENCEDESCRIPTIONWORKING SURFACETOPICAL VOLUMEHYPODERMIS THICKNESSINJECTION VOLUMEEX VIVO CULTURE DURATIONPLATE FORMATVOLUME OF MEDIUM/DAY
INF001InflammaSkin2.54 cm210-20µLN/AN/A7 days6 wells2mL
INF002Hypo-InflammaSkin2.54 cm210-20µL10mm25-45µL7 days6 wells2mL

FOR MORE DETAILS ON INFLAMMASKIN AND ITS APPLICATIONS...

Please don’t hesitate to contact us.